Product Information
THEO-24 ER 200 MG CAPSULE is a brand (anda) product labeled by Endo USA Inc., priced at $5.6678 per EA under NDC 52244020010. Its NADAC has been published 599 times since Jan 14, 2015.
FDA first approved this application on Aug 22, 1983.
Strength
200 mg/1
Manufacturer
Endo USA Inc.NDC
52244020010
Classification
Brand (ANDA)
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
THEOPHYLLINE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA087943FDA Approved
8/22/1983
On Market Since
8/25/2014
Pharmacological Classes
Price Statistics
The NADAC for THEO-24 ER 200 MG CAPSULE has been published 599 times since Jan 14, 2015, and over the history we have for it it has risen 188.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.6678 per EA |
|---|---|
| All-time high | $5.6678 (Sep 30, 2026) |
| All-time low | $1.9671 (Jan 14, 2015) |
| 52-week high | $5.6678 |
| 52-week low | $5.5027 |
| Median price | $3.4540 |
| Average price | $3.7368 |
| Largest weekly change | +10.4% (Oct 21, 2015) |
| Weeks tracked | 599 |
| Tracking since | Jan 14, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the theophylline anhydrous market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
theophylline anhydrous market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEO-24 ER 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for THEO-24 ER 200 MG CAPSULE, manufactured by Endo USA Inc., is $5.6678 per EA (NDC 52244020010), effective Sep 30, 2026.
How has the price of THEO-24 ER 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for THEO-24 ER 200 MG CAPSULE has risen 188.1%. It has been tracked across 599 weekly CMS publications since Jan 14, 2015.
What are the highest and lowest recorded NADAC prices for THEO-24 ER 200 MG CAPSULE?
Since Jan 14, 2015, the NADAC for THEO-24 ER 200 MG CAPSULE has ranged from a low of $1.9671 (Jan 14, 2015) to a high of $5.6678 (Sep 30, 2026), with a median of $3.4540 per EA.
Are there cheaper alternatives to THEO-24 ER 200 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of THEO-24 ER 200 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures THEO-24 ER 200 MG CAPSULE?
THEO-24 ER 200 MG CAPSULE (NDC 52244020010) is labeled by Endo USA Inc., and CMS classifies it as a brand (anda) product.